Trial Profile
A study of cannabidiol as treatment for early psychosis
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 04 Jan 2019
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Psychotic disorders
- Focus Adverse reactions; Therapeutic Use
- 17 Dec 2018 According to an INSYS Therapeutics, Inc. media release, this study is expected to be opened in the first half of 2019.
- 15 Sep 2018 New trial record
- 04 Sep 2018 According to an INSYS Therapeutics media release, this trial is being conducted under collaboration with the University of California (UC) San Diego School of Medicines Center for Medicinal Cannabis Research (CMCR) and is expected to commence in 2019.